Giant Cell Tumour of Bone (GCTB) Explained

What Is a Giant Cell Tumour of Bone?

A giant cell tumour of bone (GCTB), historically called an osteoclastoma, is a primary bone tumour that grows inside the bone and slowly eats it away. Under the microscope it is made of sheets of mononuclear "stromal" cells scattered with very large, multinucleated cells that look like the body's own bone-dissolving cells (osteoclasts) — these are the "giant cells" that give the tumour its name. It is the stromal cells, not the giant cells, that are the true neoplastic engine of the tumour.

The most important thing to understand about a GCTB is its behaviour. It is graded as a benign tumour, yet it is described as "locally aggressive" — meaning that while it does not usually spread around the body the way a cancer does, it can expand, thin and break through the cortex of the bone, push into the nearby joint, and almost always comes back if it is not removed thoroughly. Because of this in-between behaviour, GCTB sits in a grey zone between a simple benign cyst and a true malignant bone sarcoma, and it must be treated by a surgeon who manages bone tumours regularly. You can see where it fits among the other bone lesions on our guide to the types of bone sarcoma, and explore the whole subject area from our sarcoma — overview hub.

Who Gets It, and Where

GCTB has a very recognisable signature. It overwhelmingly affects young adults between 20 and 40 years of age whose bones have finished growing, with a slight tendency to affect women. It nearly always begins at the epiphysis — the very end of a long bone, right up against the joint — and the classic sites are around the knee (the lower end of the femur or the upper end of the tibia), the lower end of the radius at the wrist, and the upper end of the humerus. In the spine, it favours the sacrum. This combination — a young adult, a joint-end location, and the X-ray appearance below — is so characteristic that an experienced radiologist will often suspect GCTB before the biopsy result is even back.

Symptoms and the "Soap-Bubble" X-ray

Because a GCTB grows at the end of a bone right beside a joint, its symptoms are usually centred on that joint and build up over weeks to months:

• A deep, persistent ache near a joint — most commonly the knee or wrist — that is often worse with use and does not settle like a sprain
• Swelling or a firm lump over the end of the bone as the tumour expands the cortex
• Reduced or painful joint movement, sometimes with fluid building up in the joint
• A fracture through weakened bone (a pathological fracture) after a minor knock — sometimes the first sign of all

The plain X-ray is where GCTB first reveals itself. It typically shows a "lytic" lesion — a hole where bone has been dissolved — that sits eccentrically at the very end of the bone, reaching up to the joint surface. There is usually no rim of new bone or reactive sclerosis around it, and the thinned, expanded cortex often gives a bubbly, multi-chambered look that radiologists describe as a "soap-bubble" appearance. An aggressive GCTB may break through the cortex into the surrounding soft tissue. None of these features alone proves the diagnosis, but together with the patient's age and the joint-end location they make GCTB the leading suspicion.

An MRI is always done next. It maps the exact extent of the tumour inside the bone, shows whether it has reached the joint cartilage or broken into the soft tissues, and is essential for planning whether the bone can be saved by scraping the tumour out (curettage) or whether a larger resection is needed.

Is a Giant Cell Tumour Cancer? How It Differs From a Bone Sarcoma

This is the question that brings most people to this page, and the honest answer is "mostly no, but not entirely." A GCTB is officially classified as a benign tumour, and the great majority of patients are cured by surgery and never have it spread. That is fundamentally different from a malignant primary bone cancer such as osteosarcoma or Ewing sarcoma, which spread to the lungs and require chemotherapy. You can compare GCTB directly against those true bone cancers on our overview of the types of bone sarcoma.

There are, however, three important caveats that keep a GCTB firmly in the "needs specialist care" category rather than the "harmless lump" one:

• It is locally destructive. Left alone, it will keep eating away the bone end and can wreck the joint, leading to a fracture or permanent disability.
• Rare benign lung deposits. In a small minority (roughly 1–3%), a histologically benign GCTB can throw off slow-growing deposits to the lungs — which is why a chest CT is part of staging even though they behave benignly.
• Rare malignant transformation. A very small number become a true sarcoma, either at first presentation (primary malignant GCTB) or, more often, after previous radiation or repeated recurrences.

In practice this means a GCTB should never be dismissed or simply "watched." It should be biopsied to confirm the diagnosis, staged with a chest CT, and treated and followed up by a bone tumour team — exactly the safety net that distinguishes it from a benign cyst.

How GCTB Is Diagnosed, Graded, and Staged

Because a GCTB looks similar on X-ray to a few other lesions — an aneurysmal bone cyst, a brown tumour of overactive parathyroid glands, or a chondroblastoma — the diagnosis is never made on imaging alone. It is confirmed with tissue, and the work-up follows a clear sequence.

Step 1 — Biopsy to Confirm the Diagnosis

A core needle biopsy, planned together with the surgeon so the needle track can later be removed at operation, is taken from the lesion. The pathologist confirms the characteristic mix of stromal cells and osteoclast-like giant cells, and importantly excludes a "giant-cell-rich" malignant tumour that can mimic it. Modern pathology can also test for the H3F3A (G34W) mutation, a molecular marker present in the great majority of true GCTBs, which settles the diagnosis in difficult cases.

Step 2 — Campanacci Grading

GCTB is graded on its X-ray and CT appearance using the Campanacci system, which describes how aggressive the lesion looks rather than how the cells behave under the microscope:

Step 3 — Staging the Chest

Even though a GCTB is benign, a CT scan of the chest is done to look for the rare, slow-growing lung deposits mentioned earlier. Finding them does not change the benign label, but it does change follow-up and, occasionally, treatment. This combination of biopsy, grading, and chest staging is what lets the tumour board choose the right operation with confidence.

How a Giant Cell Tumour of Bone Is Treated

Treatment has one overriding goal: remove the tumour completely while saving the joint and the limb. The right operation depends on how much bone has been destroyed, whether the joint surface can be preserved, and the Campanacci grade.

Extended Intralesional Curettage — the Workhorse Operation

For most GCTBs, the joint can be saved by extended curettage. The surgeon opens a generous window in the bone, scrapes out all of the tumour, and then — this is the part that matters most for recurrence — extends the cavity walls with a high-speed burr to grind away a further layer of bone where microscopic tumour hides. A local adjuvant such as phenol, hydrogen peroxide, or argon-beam cautery is applied to the cavity to kill remaining cells. The defect is then filled with bone cement (PMMA) or a bone graft. Done this thoroughly, curettage keeps the patient's own joint and gives a far lower recurrence rate than simple scraping alone.

Wide Resection and Reconstruction — When the Bone Is Beyond Saving

If the tumour has destroyed too much of the bone end, blown through the cortex extensively (Campanacci III), or recurred repeatedly, the joint may no longer be salvageable by curettage. In that case the affected segment is removed by a wide resection and the bone reconstructed — with a custom endoprosthesis (joint replacement), a bone graft, or, at sites such as the wrist, a fusion. The aim is still a functional, weight-bearing limb. The same limb-preserving philosophy used across our sarcoma treatment service applies here.

Denosumab — Medicine That Calms the Tumour

Denosumab is a targeted drug that blocks the RANK-ligand signal the tumour uses to recruit bone-eating giant cells. It can dramatically reduce pain and re-harden the bone, and it is especially valuable in three situations: a large aggressive tumour that is inoperable as it stands, a tumour in an awkward site such as the sacrum or spine, or to firm up the bone before surgery so a difficult curettage becomes feasible. Denosumab does not replace surgery for resectable tumours — it is a tool used alongside it, and is given with calcium and vitamin D under specialist supervision.

Recurrence, Follow-Up, and Outlook

The defining challenge of a GCTB is not spread but local recurrence. Even after a careful operation, the tumour can grow back in the same bone — usually within the first two to three years. Recurrence is more likely after simple scraping without burring or adjuvant, with very aggressive (Campanacci III) tumours, and when the lesion sits in an awkward, hard-to-clear location. This is precisely why an extended curettage with a burr and adjuvant, done by a surgeon who treats bone tumours routinely, makes such a difference — it is the thoroughness of that first operation that decides how often the disease returns.

Follow-up therefore matters as much as the surgery itself. After treatment, patients are reviewed with regular X-rays of the operated bone to catch a recurrence early — when the cement is in place, a new dark area at its edge is easy to see — and periodic chest imaging to watch for the rare benign lung deposits. A recurrence is not a disaster: a re-curettage or a resection usually controls it, and most patients keep a working limb.

The overall outlook is very good. The large majority of people with a giant cell tumour of bone are cured, keep their joint, and return to normal activity. The key is getting the right operation the first time and staying in surveillance afterwards — both of which are what a dedicated bone tumour programme is built to provide.

Indicative Cost in Hyderabad

Costs are indicative. A personalised estimate is provided after your CION consultation. EMI options and cashless support through major TPAs, Aarogyasri, CGHS, ECHS & ESI are available for eligible patients.

Why Patients Choose CION for Giant Cell Tumour Care

A GCTB is curable when the first operation is thorough and the follow-up is disciplined. Here is why patients across Telangana trust CION to get both right.

Get Clarity on Your Bone Tumour Today

If you have a soap-bubble lesion on an X-ray, a GCTB diagnosis, or a tumour that has come back, talk to a bone tumour specialist before deciding on surgery. The first operation is the one that counts.